1.Prevalence of Irritable Bowel Syndrome–like Symptoms in Japanese Patients with Inactive Inflammatory Bowel Disease.
Toshihiko TOMITA ; Yu KATO ; Mayu TAKIMOTO ; Takahisa YAMASAKI ; Takashi KONDO ; Tomoaki KONO ; Katsuyuki TOZAWA ; Yoko YOKOYAMA ; Hisatomo IKEHARA ; Yoshio OHDA ; Tadayuki OSHIMA ; Hirokazu FUKUI ; Shigemi TANAKA ; Masayuki SHIMA ; Jiro WATARI ; Hiroto MIWA
Journal of Neurogastroenterology and Motility 2016;22(4):661-669
BACKGROUND/AIMS: Few studies are available that have investigated the risk factors for overlapping irritable bowel syndrome (IBS)-like symptoms in patients with inactive inflammatory bowel disease (IBD). The present study has 3 objectives: (1) to assess the prevalence of IBS-like symptoms in Japanese patients with inactive IBD using Rome III criteria, (2) to examine the relationship of IBS-like symptoms to health related quality of life (HR-QOL), and (3) to investigate associations for developing IBS-like symptoms in patients with inactive IBD. METHODS: IBS-like symptoms were evaluated using the Rome III questionnaire for functional gastrointestinal disorders. HR-QOL and hospital anxiety and depression scale were evaluated. RESULTS: IBS-like symptoms were found in 17.5% (7/40) of patients with inactive ulcerative colitis, 27.1% (29/107) of patients with inactive Crohn’s disease (CD), and 5.3% (23/438) of healthy control subjects. The QOL level was significantly lower and anxiety score was significantly higher in inactive CD patients with IBS-like symptoms than in those without such symptoms (P = 0.003, P = 0.009). Use of anti-anxiety drugs was associated with the presence of IBS symptoms (P = 0.045). HR-QOL score was lower and anxiety score was higher in patients with inactive ulcerative colitis, but the difference was not statistically significant. CONCLUSIONS: The prevalence of IBS-like symptoms in inactive IBD patients was significantly higher than in healthy controls. Inactive CD patients with IBS-like symptoms has low QOL and anxiety; suggesting that anxiety may be associated with symptom development in such patients.
Anti-Anxiety Agents
;
Anxiety
;
Asian Continental Ancestry Group*
;
Colitis, Ulcerative
;
Depression
;
Gastrointestinal Diseases
;
Humans
;
Inflammatory Bowel Diseases*
;
Irritable Bowel Syndrome
;
Prevalence*
;
Quality of Life
;
Risk Factors
2.Irritable Inflammatory Bowel Syndrome as a Distinct Disease Entity.
Journal of Neurogastroenterology and Motility 2016;22(4):545-546
No abstract available.
3.Symptomatic Improvement of Gastroparesis with Granisetron Transdermal System.
Journal of Neurogastroenterology and Motility 2016;22(4):543-544
No abstract available.
Gastroparesis*
;
Granisetron*
4.Thickened Internal Anal Sphincter Has Been Reported to Be a Typical Finding in Solitary Rectal Ulcer Syndrome.
Tae Hee LEE ; Su Jin HONG ; Joon Seong LEE
Journal of Neurogastroenterology and Motility 2015;21(1):140-141
No abstract available.
Anal Canal*
;
Ulcer*
8.Delayed Dysphagia After Removal of Foreign Bodies Near Upper Esophageal Sphincter.
Journal of Neurogastroenterology and Motility 2013;19(4):540-541
No abstract available.
Deglutition Disorders*
;
Esophageal Sphincter, Upper*
;
Foreign Bodies*
9.Esophageal Dysmotility in Gillespie Syndrome.
Bruna DELL'ACQUA CASSAO ; Daniel Tavares DE REZENDE ; Luciana C SILVA ; Fernando A M HERBELLA
Journal of Neurogastroenterology and Motility 2013;19(4):538-539
No abstract available.
Aniridia
;
Cerebellar Ataxia
;
Esophageal Motility Disorders*
;
Intellectual Disability
10.Technique of Functional and Motility Test: How to Perform Biofeedback for Constipation and Fecal Incontinence.
Hyo Jeong LEE ; Kee Wook JUNG ; Seung Jae MYUNG
Journal of Neurogastroenterology and Motility 2013;19(4):532-537
Biofeedback therapy is an instrument-based learning process centered on operant conditioning. The goal of biofeedback therapy in defecatory disorders is to strengthen the pelvic floor muscles, retrain rectal sensation and coordinate pelvic floor muscles during evacuation. Biofeedback therapy, in a broader sense, includes education, counseling, and diaphragmatic muscle training as well as exercise, sensory, and coordination training. For dyssynergic defecation, biofeedback therapy is a well-known and useful treatment option that had response rates of approximately 70-80% in randomized controlled trials. Biofeedback therapy for dyssynergic defecation consists of improving the abdominal push effort together with biofeedback technique-guided pelvic floor relaxation followed by simulated defecation and/or sensory training. For fecal incontinence, the results of a randomized controlled trial, which had a response rate of 76%, indicated that biofeedback therapy is useful in selected patients who fail to respond to conservative treatment and that training to enhance rectal discrimination of sensation may be helpful in reducing fecal incontinence. The focus of biofeedback therapy for fecal incontinence is on exercising external sphincter contractions under instant feedback, either alone or synchronously with rectal distension and/or sensory training. Biofeedback therapy is a safe treatment that may produce durable improvement beyond the active treatment period; however, a well-designed study to establish a standard protocol for biofeedback therapy is needed. This review discusses the technique of biofeedback therapy to achieve the goal and clinical outcomes for constipation and fecal incontinence.
Biofeedback, Psychology*
;
Conditioning, Operant
;
Constipation*
;
Counseling
;
Defecation
;
Discrimination (Psychology)
;
Fecal Incontinence*
;
Humans
;
Learning
;
Muscles
;
Pelvic Floor
;
Relaxation
;
Sensation
;
Treatment Outcome